Discontinued — last reported Q4 '22
Products & Services · Development of product candidate expense
Mosunetuzumab — Development of product candidate expense
Biogen Mosunetuzumab — Development of product candidate expense remained flat by 0.0% to $5.00M in Q4 2022 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $5.00M to $5.00M.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2021
Last reportedQ4 2022
How to read this metric
High development costs indicate active, potentially late-stage clinical trials, while a drop may signal the completion of a trial phase or project termination.
Detailed definition
Refers to the specific costs associated with the clinical development and regulatory advancement of a product candidate....
Peer comparison
Comparable to 'clinical trial expenses' or 'program-specific development costs' reported by other biotech firms.
Metric ID:
biib_segment_mosunetuzumab_development_of_product_candidate_expenseHistorical Data
2 years
| FY'21 | FY'22 | |
|---|---|---|
| Value | $20.00M | $20.00M |
| YoY Change | — | +0.0% |
Range$20.00M – $20.00M
Avg YoY Growth+0.0%
Median YoY Growth+0.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's mosunetuzumab — development of product candidate expense?
- Biogen (BIIB) reported mosunetuzumab — development of product candidate expense of $5.00M in Q4 2022.
- How has Biogen's mosunetuzumab — development of product candidate expense changed year-over-year?
- Biogen's mosunetuzumab — development of product candidate expense decreased by 0.0% year-over-year, from $5.00M to $5.00M.
- What does mosunetuzumab — development of product candidate expense mean?
- Direct costs incurred to advance a specific drug candidate through clinical trials.